Posted by Michael Bell on January 23, 2005, at 9:58:39
In reply to Re: Nardil kicks @ss!, posted by TheOutsider on January 20, 2005, at 5:21:24
I believe these are the CCK-B antagonists in development. Some may be derivatives of the others listed. I think that GW150013 is in the Phase II clinical trial period and is being developed by GlaxoSmithKline. CR 2945 may also be in Phase I or Phase II. Some of the others may have been discontinued.
L-365,260
CR 2945
PD134308
PD135158
L-736,380
GW150013P.S. Proglumide is a cck-b antagonist that is already on the market, but it has a weak affinity for the receptors, is very difficult to find and is very expensive. Plus it was developed specifically for gastrointestinal disorders (as opposed to anxiety), and although gastro receptors are exactly the same as CCK-B receptors, there is the problem of the blood brain barrier. Nevertheless, my short experience with Proglumide leads me to believe that a more potent and highly specific CCK-B antagonist will be very effective for anxiety if it ever hits the market.
Later.
poster:Michael Bell
thread:444453
URL: http://www.dr-bob.org/babble/20050119/msgs/446161.html